Additionally, other groups have also reported the overexpression of ROR1 in ovarian cancer patients and linked to poor clinical outcome and increased capacity of spheroid formation.29, 30 Here we have additionally shown that these receptors may enhance chemoresistance, and that knockdown may sensitise these cells to cisplatin. The gene discussed is ROR1; the disease is ovarian carcinoma.